Last reviewed · How we verify

Hepsera and lamivudine

University of Washington · FDA-approved active Small molecule

Hepsera and lamivudine is a Nucleoside/nucleotide reverse transcriptase inhibitor Small molecule drug developed by University of Washington. It is currently FDA-approved for Chronic hepatitis B infection, Hepatitis B with lamivudine-resistant virus.

Hepsera (adefovir dipivoxil) and lamivudine are nucleoside/nucleotide reverse transcriptase inhibitors that block viral replication in hepatitis B by inhibiting the reverse transcriptase enzyme.

Hepsera (adefovir dipivoxil) and lamivudine are nucleoside/nucleotide reverse transcriptase inhibitors that block viral replication in hepatitis B by inhibiting the reverse transcriptase enzyme. Used for Chronic hepatitis B infection, Hepatitis B with lamivudine-resistant virus.

At a glance

Generic nameHepsera and lamivudine
SponsorUniversity of Washington
Drug classNucleoside/nucleotide reverse transcriptase inhibitor
TargetHepatitis B virus reverse transcriptase
ModalitySmall molecule
Therapeutic areaVirology/Hepatology
PhaseFDA-approved

Mechanism of action

Both drugs are nucleoside/nucleotide analogs that inhibit hepatitis B virus (HBV) reverse transcriptase, preventing viral DNA synthesis and replication. Adefovir is a nucleotide analog with activity against both wild-type and lamivudine-resistant HBV, while lamivudine is a nucleoside analog. When used in combination, they provide complementary antiviral activity and reduce the risk of resistance development.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Hepsera and lamivudine

What is Hepsera and lamivudine?

Hepsera and lamivudine is a Nucleoside/nucleotide reverse transcriptase inhibitor drug developed by University of Washington, indicated for Chronic hepatitis B infection, Hepatitis B with lamivudine-resistant virus.

How does Hepsera and lamivudine work?

Hepsera (adefovir dipivoxil) and lamivudine are nucleoside/nucleotide reverse transcriptase inhibitors that block viral replication in hepatitis B by inhibiting the reverse transcriptase enzyme.

What is Hepsera and lamivudine used for?

Hepsera and lamivudine is indicated for Chronic hepatitis B infection, Hepatitis B with lamivudine-resistant virus.

Who makes Hepsera and lamivudine?

Hepsera and lamivudine is developed and marketed by University of Washington (see full University of Washington pipeline at /company/university-of-washington).

What drug class is Hepsera and lamivudine in?

Hepsera and lamivudine belongs to the Nucleoside/nucleotide reverse transcriptase inhibitor class. See all Nucleoside/nucleotide reverse transcriptase inhibitor drugs at /class/nucleoside-nucleotide-reverse-transcriptase-inhibitor.

What development phase is Hepsera and lamivudine in?

Hepsera and lamivudine is FDA-approved (marketed).

What are the side effects of Hepsera and lamivudine?

Common side effects of Hepsera and lamivudine include Nephrotoxicity (renal dysfunction), Headache, Asthenia/fatigue, Abdominal pain, Lactic acidosis.

What does Hepsera and lamivudine target?

Hepsera and lamivudine targets Hepatitis B virus reverse transcriptase and is a Nucleoside/nucleotide reverse transcriptase inhibitor.

Related